AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SBIR grant will help fund preclinical development of HER-2/neu peptide vaccine.
2003 SEP 10 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corp. (GNBT) announced receipt of a small business innovative research (SBIR) award from the National Cancer Institute to develop a T-helper cell breast cancer vaccine.
This novel vaccine stimulates the immune system to segments of HER-2/neu, a dominant antigen found on cancer cells. HER-2/neu is also the target of the Herceptin antibody.
The novel T-helper cell stimulating vaccine is being developed by Antigen Express, Generex's immunomedicines subsidiary in Worcester, Massachusetts. It is based on technology in several awarded U.S. patents invented by Antigen Express scientists.
The vaccine may be used to treat breast cancer. Breast cancer cells sometimes have spread by the time of surgical removal of the primary tumor. To enhance the immune system's control of that metastatic disease, patients may be vaccinated against epitopes recognized by their T-helper cells. Boosting that response in turn leads to a more effective T-killer cell response against the metastatic disease.
This method of immunizing T-helper cells may also be done in tissue culture of the patient's T-cells. The in culture-multiplied T-helper cells can then be re-infused into the patient, for an even more potent anticancer immunotherapy. Also, the vaccine peptide can be used in diagnostic tests, to monitor the strength of a patient's immune response to the cancer. Such a diagnostic test helps physicians in knowing how well ...
- Antigen Express Announces Phase I SBIR Grant for Development of MHC Class II...
- Press release article from: PR Newswire April 5, 2001 700+ words
...therapeutics. Antigen Express researchers have...cells expressing MHC Class II molecules can...do not express MHC Class II. Using a highly...cancer cell line, Antigen Express researchers aim to first induce MHC Class II and suppress...
- PRESS RELEASE: Antigen Express announces Phase I SBIR grant for development of...
- News wire article from: Chemical Business Newsbase April 11, 2001 700+ words
...on the modulation of MHC Class II molecule expression...based therapeutics. Antigen Express researchers have shown...cancer cells expressing MHC Class II molecules can serve...is suppressed. The Antigen Express strategies together...
- Antigen Express Announces Patent Award and $301,000 Phase I SBIR Grant for...
- Press release article from: PR Newswire June 3, 2002 700+ words
...WORCESTER, Mass. -- Antigen Express, Inc. (AgExp...concerning its Ii-Key MHC Class II Platform Technology...cell responses. Antigen Express Scientists have...Ii-Key Hybrid MHC Class II Platform Technology...are centered on MHC Class II antigen ...
- Ii-Key/MHC class II epitope hybrid peptide vaccines show promise for HIV.
- Newspaper article from: Health & Medicine Week January 26, 2004 700+ words
...colleagues at Antigen Express, Inc. in Worcester...The Ii-Key/MHC class II epitope hybrid...Th2 responses to MHC class II epitopes for...Vaccine (Ii-Key/MHC class II epitope hybrid...contact Minzhen Xu, Antigen Express Inc., 100 Barber...
- MHC class I-restricted alloreactive CD4 T cells identified.
- Newspaper article from: Biotech Week July 7, 2004 700+ words
...NewsRx.com & NewsRx.net) -- A set of MHC class I-restricted alloreactive CD4 cells has been...recognize major histocompatibility complex (MHC) class II molecules, MHC class I-reactive CD4+ T cells have occasionally...
- Aberrant MHC class II expression not sufficient to induce thyroid autoimmunity.
- Newspaper article from: Biotech Week June 30, 2004 700+ words
...com & NewsRx.net) -- Aberrant MHC class II expression alone is not sufficient...of major histocompatibility complex (MHC) class II molecules on thyrocytes has been demonstrated...However, the role of this aberrant MHC class II in disease development is controversial...
- HPV16-associated, MHC class I+ tumors more susceptible than class I- to...
- Newspaper article from: Virus Weekly April 8, 2003 700+ words
...effective in mice carrying HPV16-associated, MHC class I+ tumors than in those carrying and class...examined in mice carrying HPV16-associated, MHC class I+ (TC-1), and MHC class P (MK16) tumors. Intraperitoneal treatment...
- HPV16-associated, MHC class I+ tumors more susceptible than class I- to therapy.
- Newspaper article from: Vaccine Weekly April 9, 2003 700+ words
...effective in mice carrying HPV16-associated, MHC class I+ tumors than in those carrying and class...examined in mice carrying HPV16-associated, MHC class I+ (TC-1), and MHC class P (MK16) tumors. Intraperitoneal treatment...
- Exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
- Newspaper article from: Biotech Week April 28, 2004 700+ words
...derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells...eradication. Because DC can secrete MHC class I-bearing exosomes, we addressed whether...subserve the DC function consisting in MHC class I-restricted, peptide-specific CTL...
- GPC Biotech AG and Debiopharm S.A. Announce Partnering of Small Molecule MHC...
- News wire article from: Europe Intelligence Wire December 17, 2004 700+ words
...Biotech's pre-clinical small molecule MHC class II antagonists program. Under the agreement...About GPC Biotech's small molecule MHC class II antagonists program outlicensed to...responds to the foreign antigens. The MHC class II molecule plays an important role in...
Source: HighBeam Research, SBIR grant will help fund preclinical development of HER-2/neu...